Pharmaceuticals

Non Hodgkin Lymphoma (NHL) Market Outlook 2026–2030: Key Business Drivers and Trends

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the non hodgkin lymphoma (nhl) market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Non Hodgkin Lymphoma (NHL) Market by the end of 2030?

The non hodgkin lymphoma (nhl) market size has experienced robust expansion in recent years. Forecasts indicate it will expand from $10.86 billion in 2025 to reach $11.73 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 8.0%. Historically, this growth has been driven by several factors, including a global increase in NHL incidence, advancements in chemotherapy protocols, rising healthcare spending, greater public awareness of lymphatic cancers, and the development of oncology hospital facilities.

The non hodgkin lymphoma (nhl) market is anticipated to experience substantial expansion over the next few years, projected to reach $16.44 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.8%. This growth during the forecast period is driven by factors such as the expanding pipeline of targeted therapies, increasing approvals of biologics, the rising adoption of personalized medicine, broadening access in emerging markets, and an increase in stem cell transplant procedures. Significant trends expected in this period include the growing embrace of immunotherapy and targeted therapy, a rise in the use of combination treatment regimens, an increased emphasis on early and accurate diagnosis, the expansion of personalized treatment protocols, and a shift towards outpatient and home-based care models.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

What Drivers Are Shaping Future Opportunities In The Non Hodgkin Lymphoma (NHL) Market?

The elevated occurrence of non-Hodgkin lymphoma is projected to stimulate the expansion of the non-Hodgkin lymphoma market. This particular cancer forms within the lymphatic system, which is an integral part of the body’s immune defenses. The prevalence of non-Hodgkin lymphoma specifically denotes the count of individuals within a population who are presently diagnosed with or living with this ailment at a particular juncture. Treatments for non-Hodgkin lymphoma are designed to enhance outcomes for diagnosed individuals by targeting and managing cancerous cells. As an illustration, in January 2023, the American Cancer Society, a US-based cancer health organization, reported that non-Hodgkin lymphoma constitutes 4% of all cancers, and in 2023, it is predicted to affect approximately 80,550 Americans, including 44,880 males and 35,670 females. Additionally, the society estimates that 20,180 people will die in 2023 due to non-Hodgkin lymphoma. Consequently, the significant prevalence of non-Hodgkin lymphoma serves as a key impetus for the non-Hodgkin lymphoma market.

Which Segment Groups Are Influencing The Non Hodgkin Lymphoma (NHL) Market?

The non hodgkin lymphoma (nhl) market covered in this report is segmented –

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma

2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

What Industry Trends Are Transforming The Non Hodgkin Lymphoma (NHL) Market?

Leading companies within the non-Hodgkin lymphoma market are intensifying their efforts to launch innovative immunotherapies, specifically Epcoritamab-bysp (EPKINLY), aiming to secure a competitive advantage. Epcoritamab-bysp (EPKINLY) is an experimental subcutaneous immunotherapy developed to target CD20-expressing B-cell malignancies, demonstrating encouraging outcomes in clinical trials, especially for relapsed or refractory B-cell non-Hodgkin lymphoma. An example of this is AbbVie Inc., a US-based pharmaceutical company, which secured a breakthrough therapy designation (BTD) from the United States Food and Drug Administration for Epcoritamab-bysp (EPKINLY) in November 2023. This designation was awarded for its use in treating adult patients diagnosed with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more therapies. Furthermore, the European Medicines Agency (EMA) has validated a Type II application for epcoritamab (TEPKINLY) concerning the identical indication. These developments draw support from earlier published findings of the Phase 1/2 EPCORE NHL-1 clinical trial. This trial assessed the safety and initial effectiveness of subcutaneous epcoritamab in 128 adult patients afflicted with relapsed, progressive, or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma (NHL), encompassing FL.

Who Are The Major Companies Operating In The Non Hodgkin Lymphoma (NHL) Market?

Major companies operating in the non hodgkin lymphoma (nhl) market are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Non Hodgkin Lymphoma (NHL) Market?

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Non Hodgkin Lymphoma (NHL) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10676&type=smp

Browse Through More Reports Similar to the Global Non Hodgkin Lymphoma (NHL) Market 2026, By The Business Research Company

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795